Sab biotherapeutics to present at the needham virtual healthcare conference

Miami, fl , april 04, 2024 (globe newswire) -- sab biotherapeutics, inc. (nasdaq:  sabs ), (“sab” or the “company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (higg) for delaying the onset or progression of type 1 diabetes (t1d), today announced samuel j. reich, the company's chairman and ceo, will present an overview of the company at the upcoming 23rd annual needham virtual conference on thursday, april 11, 2024 at 1:30 p.m. et.
SABS Ratings Summary
SABS Quant Ranking